Newsletter Archive

31. 01.26.26 -- A Multi-Omics Approach For Characterizing Clinical-Scale iPSC Batches 1/26/2026
    01/26/26 Bioprocess Online Newsletter
32. 01.23.26 -- Data Governance And Regulations For AI Use In GMP With Peter Baker 1/23/2026
    01/23/26
33. 01.23.26 -- STREAM Edition: How To Strategically Integrate New Technology Into Existing Workflows 1/23/2026

    01/23/26 Bioprocess Online Newsletter

34. 01.22.26 -- Metrics, Not Audits, Should Lead Vendor Accountability 1/22/2026
    01/22/26 Bioprocess Online Newsletter
35. 01.21.26 -- Avoiding Protein Purification Artifacts That Still Undermine Drug Design 1/21/2026
    01/21/26 Bioprocess Online Newsletter
36. 01.20.26 -- Microbial Monitoring That Supports Annex 1 Compliance 1/20/2026

    01/20/26 Bioprocess Online Newsletter

37. 01.20.26 -- Deploying A Vendor Life Cycle Oversight Model 1/20/2026
    01/20/26 Bioprocess Online Newsletter
38. 01.19.26 -- Moving Leukopaks From GTP To GMP Is One Cell Therapy Trend To Watch In '26 1/19/2026
    01/19/26 Bioprocess Online Newsletter
39. 01.16.26 -- STREAM Edition: Why Biopharma's Tech Adoption Seems Slow 1/16/2026

    01/16/26 Bioprocess Online Newsletter

40. 01.16.26 -- Biosimilar Manufacturing Complexity Demands Mastery, Not Mimicry 1/16/2026
    01/16/26 Bioprocess Online Newsletter